Top Movers

Company Announcements

Director/PDMR Shareholding

Related Companies

By LSE RNS

RNS Number : 4613W
Redx Pharma plc
14 November 2017
 

REDX PHARMA PLC

("Redx" or "the Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

 

Alderley Park, November 14 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, announces that is has been notified that Iain Ross, Executive Chairman, has today acquired 348,000 Redx ordinary shares at a price of 18.036 pence per share.  Following this, Mr Ross will hold 348,000 ordinary shares in the Company, representing 0.28 per cent. of the issued share capital.

 

Mr Ross purchased the shares through his self-invested personal pension (SIPP) and the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Iain Ross

2

Reason for the notification

a)

Position/status 

Executive Chairman

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma plc

b)

LEI

213800HMS4EBXO589Y37

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary shares of 1 pence

 

ISIN: GB00BSNB6S51

b)

Nature of the transaction

Purchase of shares through self-invested personal pension (SIPP)

c)

Price(s) and volume(s)

348,000 ordinary shares at a price of 18.036 pence per share

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

14 November 2017 

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

 

For further information, please contact:

 

Redx Pharma Plc

T: +44 1625 469 918

Iain Ross, Executive Chairman

 



Cantor Fitzgerald Europe (Nominated Advisor & Broker)

 T: +44 20 7894 7000

Phil Davies

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

 

About Redx Pharma Plc

 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of oncology and fibrosis that address significant unmet medical need. Redx has a significant in-house discovery team with proven world-class chemistry capabilities.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHUSUARBVAAAAA

Top of Page